High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL fa...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Leukemia
Year: 2017, Jahrgang: 31, Heft: 12, Pages: 2623-2629 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2017.170 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2017.170 Verlag, Volltext: https://www.nature.com/articles/leu2017170 
|
| Verfasserangaben: | B. Kasenda, G. Ihorst, R. Schroers, A. Korfel, I. Schmidt-Wolf, G. Egerer, L. von Baumgarten, A. Röth, J. Bloehdorn, R. Möhle, M. Binder, U. Keller, M. Lamprecht, M. Pfreundschuh, E. Valk, H. Fricker, E. Schorb, K. Fritsch, J. Finke and G. Illerhaus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576948560 | ||
| 003 | DE-627 | ||
| 005 | 20220814180718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180628s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2017.170 |2 doi | |
| 035 | |a (DE-627)1576948560 | ||
| 035 | |a (DE-576)506948560 | ||
| 035 | |a (DE-599)BSZ506948560 | ||
| 035 | |a (OCoLC)1341012981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kasenda, Benjamin |d 1980- |e VerfasserIn |0 (DE-588)1115504932 |0 (DE-627)869831011 |0 (DE-576)477809014 |4 aut | |
| 245 | 1 | 0 | |a High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma |b a prospective multicentre trial by the German Cooperative PCNSL study group |c B. Kasenda, G. Ihorst, R. Schroers, A. Korfel, I. Schmidt-Wolf, G. Egerer, L. von Baumgarten, A. Röth, J. Bloehdorn, R. Möhle, M. Binder, U. Keller, M. Lamprecht, M. Pfreundschuh, E. Valk, H. Fricker, E. Schorb, K. Fritsch, J. Finke and G. Illerhaus |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Advance online publication, 16 June 2017 | ||
| 500 | |a Gesehen am 28.06.2018 | ||
| 520 | |a To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting. | ||
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 31(2017), 12, Seite 2623-2629 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma a prospective multicentre trial by the German Cooperative PCNSL study group |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:12 |g pages:2623-2629 |g extent:7 |a High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma a prospective multicentre trial by the German Cooperative PCNSL study group |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2017.170 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/leu2017170 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180628 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1576948560 |e 3014636347 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Kasenda, Benjamin","given":"Benjamin","role":"aut","family":"Kasenda"},{"family":"Egerer","role":"aut","given":"Gerlinde","display":"Egerer, Gerlinde"}],"name":{"displayForm":["B. Kasenda, G. Ihorst, R. Schroers, A. Korfel, I. Schmidt-Wolf, G. Egerer, L. von Baumgarten, A. Röth, J. Bloehdorn, R. Möhle, M. Binder, U. Keller, M. Lamprecht, M. Pfreundschuh, E. Valk, H. Fricker, E. Schorb, K. Fritsch, J. Finke and G. Illerhaus"]},"physDesc":[{"extent":"7 S."}],"id":{"eki":["1576948560"],"doi":["10.1038/leu.2017.170"]},"note":["Advance online publication, 16 June 2017","Gesehen am 28.06.2018"],"relHost":[{"pubHistory":["Nachgewiesen 11.1997 -"],"part":{"year":"2017","text":"31(2017), 12, Seite 2623-2629","volume":"31","pages":"2623-2629","extent":"7","issue":"12"},"language":["eng"],"title":[{"title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"recId":"32046699X","note":["Gesehen am 15.03.04"],"id":{"issn":["1476-5551"],"zdb":["2008023-2"],"eki":["32046699X"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma a prospective multicentre trial by the German Cooperative PCNSL study groupLeukemia"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"recId":"1576948560","type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"a prospective multicentre trial by the German Cooperative PCNSL study group","title":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma","title_sort":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma"}],"language":["eng"]} | ||
| SRT | |a KASENDABENHIGHDOSECH2017 | ||